Try our beta test site

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab (LCCC0921)

This study has been completed.
Information provided by (Responsible Party):
UNC Lineberger Comprehensive Cancer Center Identifier:
First received: December 7, 2010
Last updated: July 28, 2016
Last verified: July 2016
This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its growth.

Condition Intervention Phase
Lung Cancer
Drug: Pazopanib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center Open Label Phase II Study of Pazopanib in Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

Resource links provided by NLM:

Further study details as provided by UNC Lineberger Comprehensive Cancer Center:

Primary Outcome Measures:
  • Disease Control Rate [ Time Frame: Eight (8) months w additional time for response date to mature ]
    CR + PR + SD lasting equal to or greater than 12 weeks as defined by RECIST v1.1 in patients treated with pazopanib alone for stage IIIB/IV non-squamous NSCLC after progression on first line therapy containing bevacizumab

Secondary Outcome Measures:
  • Combined Response Rate (CR + PR) of Pazopanib According to RECIST v1.1 [ Time Frame: 8 months with additional time for response to mature ]
    estimate of combined response rate (Complete Response (CR) + Partial Response (PR) per RECIST v1.1

  • Progression Free Survival [ Time Frame: Eight (8) months w additional time for response date to mature ]
    Progression free survival is defined as time of enrollment until disease progression or death

  • Overall Survival [ Time Frame: Eight (8) months w additional time for response date to mature ]
    Overall survival is defined as the time of enrollment until death

Enrollment: 15
Study Start Date: December 2010
Study Completion Date: October 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Intervention
Subjects will take Pazopanib, 800 mg daily by mouth throughout the time in study
Drug: Pazopanib
Pazopanib, 800 mg by mouth daily each 21 day cycle

Detailed Description:

This multi-centered phase II trial will examine pazopanib stage IIIB/IV non-squamous NSCLC patients who have progressed on first-line therapy containing bevacizumab. Treatment should continue until disease progression, unacceptable toxicity, study withdrawal, or death. Patients who progress will be treated at the discretion of their physician. all patients who initiate treatment will be evaluated for disease control rate, which is the primary endpoint of this study.

The primary objective is to estimate the disease control rate of pazopanib alone in patients with stage IIIB/IV non-squamous NSCLC who progressed while on bevacizumab. Disease control rate id defined as complete (CR) + partial response (PR) + stable disease (SD) lasting greater than or equal to 12 weeks as defined by RECIST.

Secondary Objectives To estimate the combined response rate (CR + PR) of pazopanib according to RECIST To estimate the progression free survival (defined as time of enrollment until disease progression or death) and overall survival (defined as time of enrollment until death) of patients treated with pazopanib.

To evaluate the safety and tolerability of pazopanib using the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 4.0 To explore potential correlations between blood biomarkers and clinical response.

Pazopanib is dosed continuously throughout the study. Cycle lengths are identified as 21 days for purposes of the calendar.

The treatment dosage and administration for participating subjects will be, Pazopanib, 800 mg by mouth daily during a 21 day cycle until disease progression.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 or older
  • Stage IIIB (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage IV NSCLC
  • Evidence of progression while on bevacizumab
  • Patients treated for CNS metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug

Exclusion Criteria:

  • Prior malignancy
  • Clinically significant gastrointestinal abnormalities
  • Presence of uncontrolled infection or nonhealing wound, fracture, or ulcer
  • History of cardiovascular conditions within the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01262820

United States, North Carolina
North Carolina Cancer Hospital at U of North Carolina at CH
Chapel Hill, North Carolina, United States, 27599
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15232
Sponsors and Collaborators
UNC Lineberger Comprehensive Cancer Center
Principal Investigator: Thomas Stinchcombe, MD North Carolina Cancer Hospital at University of NC at Chapel Hill
  More Information

Additional Information:
Responsible Party: UNC Lineberger Comprehensive Cancer Center Identifier: NCT01262820     History of Changes
Obsolete Identifiers: NCT01107652
Other Study ID Numbers: LCCC 0921 
Study First Received: December 7, 2010
Results First Received: July 28, 2016
Last Updated: July 28, 2016

Keywords provided by UNC Lineberger Comprehensive Cancer Center:
Non Squamous Non Small Cell Lung Cancer
After Progress on first line therapy
Using Bevacizumab

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on February 20, 2017